Published May 1985 | Version v1
Journal article

Tumor uptake of radiolabelled pyrimidine bases and pyrimidine nucleosides in animal models

  • 1. Alberta Univ., Edmonton (Canada). Faculty of Pharmacy and Pharmaceutical Sciences

Description

The tritium-labelled acyclonucleoside, N-[2-(hydroxyethoxy)methyl]-5-[3H]methyluracil (3H-3), was synthesized for evaluation as a tumor diagnostic agent. 5-[3H]-methyluracil, 3H-1, was converted to the 2,4-bis-trimethylsilyl intermediate which was coupled with 2-acetoxyethoxymethyl bromide to afford 1-[(2-acetoxyethoxy)methyl-5-[3H]methyluracil (3H-2). Treatment of 3H-2 with sodium methoxide in methanol afforded 3H-3 (specific activity 188 MBq mmol-1). The tissue distribution of 3H-3 was examined in male BDF1 mice bearing Lewis Lung (LL) carcinomas. Long bone exhibited the highest tumor: tissue ratios. The kidney contained the highest radioactivity level relative to the tumor. This suggested a major urinary route of excretion. The major radioactive blood component (89.21%) was found to have a biological half-life of 0.19 min. The title compound is unsuitable for use as a diagnostic agent for LL carcinoma because of low tumor uptake and rapid urinary elimination of injected radioactivity from the body. (author)

Additional details

Additional titles

Subtitle (English)
8. Synthesis and tissue distribution of N-[2-(hydroxyethoxy)methyl]-5-["3H]methyluracil

Publishing Information

Journal Title
Int. J. Appl. Radiat. Isot.
Journal Volume
36
Journal Issue
5
Series
Int. J. Appl. Radiat. Isot.
Journal Page Range
395-398
ISSN
0020-708X